TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02986854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
Description: One intramuscular injection of MenACWY at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
Description: One intramuscular injection of MenACWY at Day 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
Description: One intramuscular injection of MenACWY at Day 1.
Study: NCT02470884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Fully Absorbable Scaffold
Description: Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
Study: NCT03009084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
Study: NCT03095456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Spiriva Handihaler®
Description: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
Study: NCT01655017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: adipose tissue biopsy (to evaluate inflammation and fibrosis)
Study: NCT04025996

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Assessments and Eye Assessments
Description: Cardiac Assessments, include the following:~* transthoracic echocardiography~* computed tomography of coronary arteries~* position emission tomography computed tomography or single photon emission tomography computed tomography~Eye examinations, include the following:~* pupil dilation~* retinal photography~* dynamic vessel analyser~* IOL master
Study: NCT00409617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab 40 mg Every Other Week dosing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
Study: NCT02085187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine training and counselling
Description: Training and counselling by the physiotherapist consisted of 3 weekly sessions, lasting 30-45 minutes, over a 3 week period, i.e. a total of 9 supervised sessions. Heart rate and oxygen saturation were monitored during the exercise training. This included thoracic mobilization exercises, cardio training, strength training and breathing exercises. The training intensity was progressed continuously.~There were 1-2 sessions with the occupational therapist, which consisted of training and counselling on energy conservation techniques. The first session was 60 minutes long and included assessment, counselling and training. This session was delivered in the second week of the intervention. The intervention concluded in the third week, with sessions of 30 minutes as required.
Study: NCT01061658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine
Description: Lower dosage of vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01437540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide/Formoterol Fumarate
Description: Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
Study: NCT00225095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stem Cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stem Cells

Intervention type: DRUG
Group type: OTHER
Intervention: Hyaluronan
Study: NCT04563013

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation
Description: the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation
Description: the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.
Study: NCT00504374

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Symptoms questionnaire lasting about 5 to 10 minutes.
Study: NCT02427503

Intervention type: PROCEDURE
Intervention: Asthma with NP and require surgery
Description: To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.
Study: NCT03369002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: seladelpar
Description: Oral single dose 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: seladelpar
Description: Oral single dose 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: seladelpar
Description: Oral single dose 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: seladelpar
Description: Oral single dose 10 mg
Study: NCT01437540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Inhaled formoterol fumarate 12 μg, twice per day
Study: NCT01408342

Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab and Rituximab
Description: * Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3~* Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25~* Cyclosporine 3 mg/kg starting day 21
Study: NCT01707381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-303259-X
Description: Topical ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate
Description: Topical ophthalmic solution
Study: NCT02935413

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Device: verum tDCS real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes Behavioral: VRT Vision restoration training, 10 sessions, 20 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Standard rehabilitation procedures involving PC-based training of saccades and visual exploration
Study: NCT03843567

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic characterisation training
Description: Included in the training material is an overview of Resect and Discard, endoscopic platforms (NBI, BLI and i-Scan), NICE classification, SIMPLE classification, BASIC classification and example still images and videos of both classifications in use. Still images will be used to ensure participants have the best opportunity to observe and learn Kudo Pit Patterns and other polyp features without movement artefact before observing videos, which are more challenging to interpret. The training will last approximately 1 hour.
Study: NCT00375167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Workbook Training (psychoeducational training)
Description: The Recovery Workbook uses an educational process to increase awareness of recovery, increase knowledge and control of the illness, increase awareness of the importance and nature of stress, enhance personal meaning, build personal support, and develop goals and plans of action. The intervention period of 30 weekly sessions recommended by Spaniol and colleagues was shortened to 12 weekly sessions to accommodate for clinical and participant commitment. No workbook content was excluded, and all practice exercises were covered.
Study: NCT03843567

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopic characterisation training
Description: Included in the training material is an overview of Resect and Discard, endoscopic platforms (NBI, BLI and i-Scan), NICE classification, SIMPLE classification, BASIC classification and example still images and videos of both classifications in use. Still images will be used to ensure participants have the best opportunity to observe and learn Kudo Pit Patterns and other polyp features without movement artefact before observing videos, which are more challenging to interpret. The training will last approximately 1 hour.
Study: NCT04059575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (Performance Plus)
Description: PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
Study: NCT00375167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT as usual
Description: Assertive Community Treatment services provided as per established and evidence-based fidelity standards.
Study: NCT02533895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV0113 DC-CIT
Description: Mature loaded DCs will be injected intra-nodally into tumour free lymph nodes or subcutaneously close to tumour free lymph nodes at weekly intervals for at least 6 weeks.
Study: NCT04059575

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping (Gold Tex)
Description: PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
Study: NCT02533895

Intervention type: OTHER
Group type: OTHER
Intervention: Data evaluation
Description: For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.~Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data evaluation
Description: For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.~Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc
Study: NCT00093821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04569357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prospekta
Description: Oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study: NCT04629846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1209
Description: QL1209 IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
Study: NCT00742755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prospective intervention
Description: Prospective Intervention: Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
Study: NCT01865383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microfinance and Health Leadership
Description: Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
Study: NCT05030480

Intervention type: DIAGNOSTIC_TEST
Intervention: renal functions
Description: urea, creatinine, GFR
Study: NCT01581320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test group
Description: Once a month, administration of DP-R206 \& placebo for 16 weeks
Study: NCT03256253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pregabalin up to 600 mg/day
Study: NCT00769457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Access Arm
Description: Active OptiVol-System with CareAlert via CareLink
Study: NCT01581320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference group
Description: Once a month, administration of Bonviva \& placebo for 16 weeks
Study: NCT02222506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System
Description: KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers.
Study: NCT02028390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scout takes visual and thermal images of external wounds
Description: All images are taken after the wound has acclimated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImageReview's visual perimeter trace of the external wound
Description: Trace is drawn by the study staff using the ImageReview software.
Study: NCT01399866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: 2 single weekly doses, 50 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02979145

Intervention type: OTHER
Intervention: No intervention involved
Study: NCT01623739

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a dental implant
Description: Type 1 implant placement Type 2 implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a dental implant
Description: Type 1 implant placement Type 2 implant placement
Study: NCT02793791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive ablation therapies
Description: Including RFA (radiofrequency ablation);MWA (microwave ablation); PEI (percutaneous ethanol injection),etc.
Study: NCT02013245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC live vaccine
Description: Live-attenuated Mycobacterium tuberculosis vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC live vaccine
Description: Live-attenuated Mycobacterium tuberculosis vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC live vaccine
Description: Live-attenuated Mycobacterium tuberculosis vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available BCG live vaccine
Description: Live-attenuated Mycobacterium bovis vaccine
Study: NCT01224080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adiana placement
Description: All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
Study: NCT00661947

Intervention type: OTHER
Intervention: Dr Pepper sweetened with sucrose or high fructose corn syrup
Description: Comparison of different formulations of fructose.
Study: NCT03184285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline alert 1
Description: measurement in supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-Trendelenburg-position (ATB)
Description: measurement under ATB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB in narcosis
Description: measurement under ATB in narcosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline in narcosis 1
Description: measurement in supine position in narcosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: passive leg raising
Description: measurement under passive leg raising

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: volume bolus substitution
Description: measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline in narcosis 2
Description: measurement in supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: start capnoperitoneum
Description: measurement in supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB plus capnoperitoneum
Description: measurement under ATB plus capnoperitoneum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB plus capnoperitoneum plus volume bolus substitution
Description: measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB loss of capnoperitoneum
Description: measurement under ATB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline
Description: measurement in supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline alert 2
Description: measurement in supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: torso position rising 30° at the beginning
Description: measurement in the recovery unit

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: torso position rising 30° at the end
Description: measurement in the recovery unit
Study: NCT04492163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTFields
Description: TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.~Other Names:~• TTFields
Study: NCT00525733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir 800 mg
Description: darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir 800 mg
Description: darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC 200 mg/TDF 300mg
Description: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC 200 mg/TDF 300mg
Description: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)
Study: NCT02028390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImageReview's External Wound Trace Overlay
Description: Study staff overlay the trace of the visual external wound's perimeter onto the corresponding thermal image of the external wound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImageReview's unaffected reference area selected
Description: Study Staff select an unaffected reference area of an adjacent body surface.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjacent tissue trace of the wound trace overlay
Description: Study staff select an adjacent tissue trace of the wound trace overlay
Study: NCT00506025

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry Juice
Description: Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry Juice
Description: Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: De-Activated Cranberry juice
Description: De-Activated Cranberry juice in the am, then placebo (P) in the pm
Study: NCT04347005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: AR882
Description: Single dose of AR882 or matching placebo
Study: NCT00525733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir 100 mg
Description: one tablet of ritonavir is taken with darunavir daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg
Description: one tablet of ritonavir is taken with darunavir daily